Metrics to compare | GENF | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGENFPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.7x | −4.8x | −0.3x | |
PEG Ratio | −0.22 | −0.01 | 0.00 | |
Price/Book | −17.3x | 3.7x | 2.6x | |
Price / LTM Sales | 16.2x | 12.0x | 3.0x | |
Upside (Analyst Target) | - | 183.1% | 56.6% | |
Fair Value Upside | Unlock | −16.2% | 10.2% | Unlock |
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapies in the United Kingdom, Belgium, and the United States. It develops drugs in pre-clinical trial stage, including GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion for the treatment of metabolic associated steatohepatitis; GF-1003, a topical delivery of SIRT6 to the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005 for the treatment of mitochondrial dysfunction and sarcopenia; and GF-1006, an ophthalmology mRNA cent SIRT6 for the treatment of cornea pathologies and glaucoma. The company was founded in 2020 and is headquartered in London, the United Kingdom.